Charles Laney, MD
Cardiovascular Disease · Oxford, MSNPI 1184823551
Payments from drug & device makers
Across 560 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Pfizer$1K
- Philips North America LLC$793
- Merck$745
- Medtronic$661
- Johnson & Johnson$611
- plus $4K from 32 others
What the payments were for
- Food & beverage$9,627100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 76 | $1,578 |
| Pfizer | 79 | $1,146 |
| Philips North America LLC | 42 | $793 |
| Merck | 39 | $745 |
| Medtronic(2 entities) | 49 | $661 |
| Johnson & Johnson | 39 | $611 |
| Amgen | 37 | $550 |
| Novartis | 27 | $457 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 28 | $449 |
| E.r. Squibb & Sons, L.L.C. | 25 | $435 |
| Sanofi-aventis U.S. LLC | 19 | $323 |
| Boehringer Ingelheim | 14 | $217 |
| Irhythm Technologies, Inc. | 12 | $200 |
| AstraZeneca | 13 | $176 |
| Novo Nordisk | 9 | $153 |
| Boston Scientific | 5 | $139 |
| Abiomed | 5 | $116 |
| Endologix LLC | 1 | $111 |
| Bayer | 5 | $97 |
| Astellas Pharma US Inc | 5 | $88 |
| Regeneron Healthcare Solutions, Inc. | 5 | $66 |
| Inspire Medical Systems, Inc. | 2 | $62 |
| Kowa Pharmaceuticals America, Inc. | 2 | $60 |
| Lexicon Pharmaceuticals, Inc. | 4 | $57 |
| Angiodynamics, Inc. | 2 | $44 |
| Edwards Lifesciences | 1 | $38 |
| Impulse Dynamics (USA) Inc. | 2 | $37 |
| Cvrx, Inc. | 2 | $34 |
| Gilead | 2 | $30 |
| Silk Road Medical, Inc. | 1 | $20 |
| Terumo Medical Corporation | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Atricure, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $17 |
| Merit Medical Systems Inc | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Preventice Services, LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFX$111
How this compares
$9,627 in reported general payments places this provider in the 65th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 743 | $614,765 |
| JardianceEmpagliflozin | 392 | $288,255 |
| FarxigaDapagliflozin Propanediol | 366 | $253,904 |
| EntrestoSacubitril/Valsartan | 253 | $200,672 |
| MultaqDronedarone Hcl | 121 | $129,014 |
| Repatha SureclickEvolocumab | 118 | $75,949 |
| XareltoRivaroxaban | 70 | $58,006 |
| Repatha SyringeEvolocumab | 57 | $33,165 |
| BrilintaTicagrelor | 50 | $25,145 |
| Ranolazine ErRanolazine | 228 | $9,530 |
| DapagliflozinDapagliflozin Propanediol | 19 | $8,419 |
| Bumetanide | 490 | $8,342 |
| Nitroglycerin PatchNitroglycerin | 258 | $8,093 |
| Flecainide Acetate | 420 | $7,310 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 66 | $5,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,146 | $614,765743 claims |
| Boehringer IngelheimJardiance | $217 | $288,255392 claims |
| AstraZenecaFarxiga, Brilinta | $176 | $279,049416 claims |
| NovartisEntresto | $457 | $200,672253 claims |
| Sanofi-aventis U.S. LLCMultaq | $323 | $129,014121 claims |
| Johnson & JohnsonXarelto | $611 | $58,00670 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Oxford
- Mark StrongOxford$22K
- Barry BertoletTupelo$6.4M
- Dharmesh PatelSouthaven$1.9M
- James HaysJackson$782K
- John EstessTupelo$416K
- Donny StokesJackson$277K
- Mahmoud ZayedPascagoula$103K
- Benjamin BlossomTupelo$91K
- James HaysJackson$65K
- James BenslerJackson$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.